BR112017012911A2 - método para tratamento de insuficiência cardíaca - Google Patents

método para tratamento de insuficiência cardíaca

Info

Publication number
BR112017012911A2
BR112017012911A2 BR112017012911A BR112017012911A BR112017012911A2 BR 112017012911 A2 BR112017012911 A2 BR 112017012911A2 BR 112017012911 A BR112017012911 A BR 112017012911A BR 112017012911 A BR112017012911 A BR 112017012911A BR 112017012911 A2 BR112017012911 A2 BR 112017012911A2
Authority
BR
Brazil
Prior art keywords
heart failure
treating heart
treating
lvesv
individuals
Prior art date
Application number
BR112017012911A
Other languages
English (en)
Other versions
BR112017012911B1 (pt
Inventor
Golden Lee
Itescu Silviu
Original Assignee
Mesoblast Int Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014905243A external-priority patent/AU2014905243A0/en
Application filed by Mesoblast Int Sarl filed Critical Mesoblast Int Sarl
Publication of BR112017012911A2 publication Critical patent/BR112017012911A2/pt
Publication of BR112017012911B1 publication Critical patent/BR112017012911B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrotherapy Devices (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente revelação se refere a métodos para tratamento ou prevenção de insuficiência cardíaca em indivíduos com volume sistólico final do ventrículo esquerdo elevado (lvesv). em particular, a presente revelação se refere a métodos para tratamento ou prevenção de insuficiência cardíaca em indivíduos com um lvesv superior a 70 ml (> 70 ml).
BR112017012911-6A 2014-12-23 2015-12-22 Método para tratamento de insuficiência cardíaca BR112017012911B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014905243A AU2014905243A0 (en) 2014-12-23 Method for treating heart failure
AU2014905243 2014-12-23
PCT/EP2015/081042 WO2016102597A1 (en) 2014-12-23 2015-12-22 Method for treating heart failure

Publications (2)

Publication Number Publication Date
BR112017012911A2 true BR112017012911A2 (pt) 2018-01-02
BR112017012911B1 BR112017012911B1 (pt) 2021-10-05

Family

ID=55069857

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017012911-6A BR112017012911B1 (pt) 2014-12-23 2015-12-22 Método para tratamento de insuficiência cardíaca

Country Status (11)

Country Link
US (2) US11712452B2 (pt)
EP (2) EP3236977B1 (pt)
JP (3) JP6804451B2 (pt)
KR (1) KR20170095932A (pt)
CN (2) CN107257687B (pt)
AU (2) AU2015371007B2 (pt)
BR (1) BR112017012911B1 (pt)
CA (1) CA2971512A1 (pt)
ES (1) ES2956655T3 (pt)
SG (2) SG10202008024VA (pt)
WO (1) WO2016102597A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3062112A1 (en) * 2017-05-04 2018-11-08 Mesoblast International Sarl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
WO2023092043A1 (en) * 2021-11-17 2023-05-25 Silviu Itescu Method of treating progressive heart failure in subjects at high risk of poor outcomes
CN117797243A (zh) * 2022-09-30 2024-04-02 上海泽生科技开发股份有限公司 神经调节蛋白及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030204A (en) 1988-09-28 1991-07-09 Advanced Cardiovascular Systems, Inc. Guiding catheter with controllable distal tip
US5104393A (en) 1989-08-30 1992-04-14 Angelase, Inc. Catheter
US5060660A (en) 1990-02-28 1991-10-29 C. R. Bard, Inc. Steerable extendable guidewire with adjustable tip
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
EP0619748B1 (en) 1991-08-28 1995-11-08 Medtronic, Inc. Steerable stylet and manipulative handle assembly
US6251104B1 (en) 1995-05-10 2001-06-26 Eclipse Surgical Technologies, Inc. Guiding catheter system for ablating heart tissue
US6120520A (en) 1997-05-27 2000-09-19 Angiotrax, Inc. Apparatus and methods for stimulating revascularization and/or tissue growth
US6102926A (en) 1996-12-02 2000-08-15 Angiotrax, Inc. Apparatus for percutaneously performing myocardial revascularization having means for sensing tissue parameters and methods of use
US6387369B1 (en) * 1997-07-14 2002-05-14 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
DE19734220C2 (de) 1997-08-07 2000-01-13 Pulsion Verwaltungs Gmbh & Co Kathetersystem mit einem Einführungsdraht
DE69838526T2 (de) 1998-02-05 2008-07-03 Biosense Webster, Inc., Diamond Bar Gerät zum Freisetzen eines Medikaments im Herzen
US6432119B1 (en) 1999-03-17 2002-08-13 Angiotrax, Inc. Apparatus and methods for performing percutaneous myocardial revascularization and stimulating angiogenesis using autologous materials
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
AU2006244639A1 (en) * 2005-03-31 2006-11-16 Mytogen, Inc. Treatment for heart disease
EP2432482B1 (en) * 2009-05-20 2015-04-15 Cardio3 Biosciences S.A. Pharmaceutical composition for the treatment of heart diseases.
MX340185B (es) 2010-08-27 2016-06-29 Univ Miami Células precursoras cd27 1 derivadas de médula ósea para reparación cardíaca.
PT2611906T (pt) * 2010-08-31 2024-04-16 Gallant Pet Inc Terapias sistémicas com células estaminais alogénicas para tratamento de doenças em gatos e cães
US9642878B2 (en) * 2011-09-09 2017-05-09 Mesoblast, Inc. Methods for increasing osteoblastic function
CA2857545A1 (en) * 2011-11-30 2013-06-06 Advanced Cell Technology, Inc. Mesenchymal stromal cells and uses related thereto
WO2014057097A1 (en) * 2012-10-12 2014-04-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Modulated mesenchymal stem cells for cardiac cell therapy

Also Published As

Publication number Publication date
AU2021240102A1 (en) 2021-10-28
JP2018500348A (ja) 2018-01-11
WO2016102597A1 (en) 2016-06-30
US11712452B2 (en) 2023-08-01
CN107257687A (zh) 2017-10-17
EP4249056A2 (en) 2023-09-27
CA2971512A1 (en) 2016-06-30
JP7091427B2 (ja) 2022-06-27
CN114224916A (zh) 2022-03-25
JP2021035995A (ja) 2021-03-04
AU2015371007B2 (en) 2021-07-08
US20170333482A1 (en) 2017-11-23
BR112017012911B1 (pt) 2021-10-05
US20230364149A1 (en) 2023-11-16
EP3236977B1 (en) 2023-06-21
SG10202008024VA (en) 2020-10-29
CN107257687B (zh) 2021-12-03
KR20170095932A (ko) 2017-08-23
SG11201704780UA (en) 2017-07-28
ES2956655T3 (es) 2023-12-26
JP6804451B2 (ja) 2020-12-23
JP2022113802A (ja) 2022-08-04
EP3236977A1 (en) 2017-11-01
AU2015371007A1 (en) 2017-06-29
EP4249056A3 (en) 2023-10-18

Similar Documents

Publication Publication Date Title
CL2016000354A1 (es) Modulación de la inmunidad tumoral
PH12017500153A1 (en) Compositions and methods of use for treating metabolic disorders
CL2015003731A1 (es) Inhibidores de bromodominios
GB2538178A (en) Viscosifier polymer for treatment of a subterranean formation
EA033286B1 (ru) Способ лечения или отсрочки развития хронической болезни почек
UY34593A (es) Miméticos sintéticos de apelina para el tratamiento de falla cardiaca
PH12017502216A1 (en) Nucleic acid-cationic polymer compositions and methods of making and using the same
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
BR112015017427A2 (pt) artigo compreendendo um substrato polimérico e uma camada de polímero de silicone
WO2014106825A3 (en) Methods and devices for identifying improper medical reporting
MX2018002546A (es) Composiciones que comprenden un compuesto de urolitina.
BR112017022022A8 (pt) Arenavírus para uso no tratamento e/ou prevenção de tumores e método para a produção de arenavírus com propriedades de regressão de tumor (aprimoradas)
BR112017027277A2 (pt) ?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula?
BR112017012911A2 (pt) método para tratamento de insuficiência cardíaca
MX2019006090A (es) Metodos para mejorar la respuesta inmune con everolimus, dactolisib o ambos.
WO2015142865A3 (en) Metakaryocidal treatments
MX2019000677A (es) Células miméticas de células b.
PH12016502150A1 (en) Method for treating renal cell carcimona
MX2018003802A (es) Formulacion de hipericina para el diagnostico fotodinamico.
BR112017011513A2 (pt) tratamento de condições oculares usando células progenitoras
WO2017095918A3 (en) Methods for treating cancer using rspo3 antagonists
MX2018003801A (es) Formulacion de hipericina para la terapia fotodinamica.
BR112017011490A2 (pt) método para tratar condição inflamatória ou isquêmica em um órgão ou tecido de um paciente
MX2017001737A (es) Vitamina b2 y sus usos.
EA201991165A1 (ru) Способы усиления иммунного ответа с помощью эверолимуса, дактолисиба или обоих

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/12/2015, OBSERVADAS AS CONDICOES LEGAIS.